title: Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer.
abstract: Chemokine receptor CXCR3 has been proved to play an important role in tumorigenesis and tumor progression in many malignancies, but its precise efficacy on gastric cancer (GC) has not been evaluated yet. The present study was aimed to explore the correlation of chemokine receptor CXCR3 with tumor-infiltrating lymphocytes (TILs) and prognosis in advanced gastric cancer (GC). Expression of CXCR3 and CD4+, CD8+ TILs was conducted in 192 advanced GC specimens and 48 corresponding paracancerous tissues by immunohistochemical (IHC) analysis. CXCR3 expression in GC tissues was significantly higher than that in paracancerous tissues (P<0.001) and CD8+, CD4+ TILs infiltration increased with high CXCR3 expression (P=0.032 and P<0.001, respectively). Our study showed significantly lower CXCR3 expression in patients with greater tumor invasion depth and lymph node metastasis compared with patients with lesser tumor invasion depth and without lymph node metastasis (P=0.002 and P=0.001, respectively). Univariate analysis indicated that patients with high CXCR3 expression and high CD8+ TILs infiltration had longer overall survival (OS) (log-rank test, P<0.001 and P=0.002, respectively). Univariate and multivariate analyses indicated that CXCR3 expression was an independent prognostic factor for OS (P=0.002). The present study suggested that CXCR3 expression was upregulated in advanced GC and was associated with increased CD4+, CD8+ TILs infiltration and improved OS. Therefore, CXCR3 overexpression is implicated as a favorable prognostic biomarker in human advanced GC.
authors.affiliation: Department of Pathology, Dongfeng Hospital, Hubei University of Medicine Shiyan 442000, China.
authors.forename: Kai
authors.initials: K
authors.lastname: Li
authors.affiliation: Department of Pathology, Dongfeng Hospital, Hubei University of Medicine Shiyan 442000, China.
authors.forename: Zhengpeng
authors.initials: Z
authors.lastname: Zhu
authors.affiliation: Department of Pathology, Dongfeng Hospital, Hubei University of Medicine Shiyan 442000, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Luo
authors.affiliation: Department of Pathology, Dongfeng Hospital, Hubei University of Medicine Shiyan 442000, China.
authors.forename: Jingyi
authors.initials: J
authors.lastname: Fang
authors.affiliation: Department of Pathology, Dongfeng Hospital, Hubei University of Medicine Shiyan 442000, China.
authors.forename: Huanhuan
authors.initials: H
authors.lastname: Zhou
authors.affiliation: Department of Pathology, Zhongnan Hospital, Wuhan University Wuhan 430071, China.
authors.forename: Min
authors.initials: M
authors.lastname: Hu
authors.affiliation: Department of Pathology, Zhongnan Hospital, Wuhan University Wuhan 430071, China.
authors.forename: Ninu
authors.initials: N
authors.lastname: Maskey
authors.affiliation: Department of Pathology, Zhongnan Hospital, Wuhan University Wuhan 430071, China.
authors.forename: Guifang
authors.initials: G
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D054367:Receptors, CXCR3 / Q000276:immunology*; D013274:Stomach Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; C515187:CXCR3 protein, human; D054367:Receptors, CXCR3
keywords: CD4; CD8; CXCR3; Gastric cancer; biomarker; prognosis
references.citation: J Pathol. 2012 Jan;226(2):148-57
references.pmid: 21989643
references.citation: Br Med Bull. 2008;85:87-100
references.pmid: 18267927
references.citation: Biomed Pharmacother. 2012 Jul;66(5):373-7
references.pmid: 22401929
references.citation: Br J Cancer. 2011 Feb 1;104(3):469-79
references.pmid: 21179030
references.citation: Eur Urol. 2012 Feb;61(2):385-94
references.pmid: 22079021
references.citation: Acta Pathol Microbiol Scand. 1965;64:31-49
references.pmid: 14320675
references.citation: Ann Surg Oncol. 2010 Dec;17(12):3077-9
references.pmid: 20882416
references.citation: Biochim Biophys Acta. 2012 Jan;1825(1):117-29
references.pmid: 22079531
references.citation: J Urol. 2008 Jan;179(1):61-6
references.pmid: 17997430
references.citation: Cancer Sci. 2007 Nov;98(11):1652-8
references.pmid: 17894551
references.citation: Haematologica. 2007 Mar;92(3):349-56
references.pmid: 17339184
references.citation: Oncoimmunology. 2014 Jan 1;3(1):e27663
references.pmid: 24800170
references.citation: Int J Biol Sci. 2011;7(5):651-8
references.pmid: 21647333
references.citation: Adv Cancer Res. 2010;106:91-111
references.pmid: 20399957
references.citation: J Mol Histol. 2012 Dec;43(6):699-713
references.pmid: 22752457
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Int J Cancer. 2013 Jan 15;132(2):276-87
references.pmid: 22689289
references.citation: Cancer Lett. 2008 Aug 28;267(2):226-44
references.pmid: 18579287
references.citation: Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):85-8
references.pmid: 21426802
references.citation: Biochim Biophys Acta. 2013 Dec;1836(2):287-95
references.pmid: 23994549
references.citation: Chin Med J (Engl). 2014;127(3):560-7
references.pmid: 24451967
references.citation: J Urol. 2014 Aug;192(2):567-74
references.pmid: 24518777
references.citation: Biochim Biophys Acta. 2006 Sep;1762(9):811-8
references.pmid: 16934957
references.citation: World J Gastroenterol. 2014 Feb 21;20(7):1681-93
references.pmid: 24587647